

LVIS™

Stent

LVIS™ Jr.

Stent

INSTRUCTIONS FOR USE

Rx Only: Federal (USA) law restricts this device to sale by or on the order of a physician.

DEVICE DESCRIPTION

The MicroVention Low-Profile Visualized Intraluminal Support (LVIS) device [Figures 1, 2 and 3a] is a self-expanding nickel titanium, single wire braid, compliant, closed-cell design that can be deployed and retrieved by a single operator. The LVIS device is sterile and non-pyrogenic and is packaged as a single unit with an introducer sheath and a detachable push wire.

Note: “LVIS” refers to both LVIS and LVIS Jr. devices, unless otherwise specified.

Figure 1.
Device - Components





Figure 2.
Device – Implant Delivery



	Distal Markers	Helical Markers	Proximal Markers
LVIS Device	4	2	4
LVIS Jr. Device	3	3	3

Figure 3a.
Device Implant Dimensions




Table 1a: LVIS Device Product Information

Product Code	LVIS				
	Undeployed Length [†] (mm)	Total Length/ Working Length** (mm)	Total Length/ Working Length** (mm)	Total Length/ Working Length** (mm)	Total Length/ Working Length** (mm) *
			2.5 mm OD	3.0 mm OD	3.5 mm OD
212517-LVIS	28		23 / 19	20 / 16	17 / 13
212525-LVIS	40		32 / 28	27 / 23	22 / 18
			2.5 mm OD	3.0 mm OD	3.5 mm OD
212912-LVIS	18		15 / 11	14 / 10	12 / 8
212917-LVIS	31		24 / 20	21 / 17	17 / 13
212922-LVIS	44		34 / 30	29 / 25	22 / 18
212928-LVIS	57		43 / 39	37 / 33	28 / 24
212931-LVIS	64		48 / 44	41 / 37	31 / 27
			3.0 mm OD	3.5 mm OD	4.0 mm OD
213015-LVIS	34		26 / 22	22 / 18	18 / 14
213025-LVIS	49		36 / 32	31 / 27	23 / 19
213041-LVIS	71		52 / 48	44 / 40	32 / 28
			4.0 mm OD	4.5 mm OD	5.0 mm OD
214035-LVIS	67		45 / 41	39 / 35	30 / 26
214049-LVIS	76		51 / 47	43 / 39	33 / 29
	Compatible with Headway™ 21 Microcatheter (inner diameter = 0.021" or 0.53 mm)				
	* Fully expanded diameter				
	** Total Length (which includes flared ends) = Working Length + 4 mm (2 mm each side)				
	† Within Headway 21 Microcatheter (inner diameter = 0.021" or 0.53 mm)				

LVIS				
Product Code	Free Area (%)			
		2.5 mm OD	3.0 mm OD	3.5 mm OD
212517-LVIS		73	75	74
212525-LVIS		73	73	71
	2.5 mm OD	3.0 mm OD	3.5 mm OD	4.0 mm OD
212912-LVIS	76	78	80	80
212917-LVIS	74	77	77	75
212922-LVIS	74	76	76	73
212928-LVIS	74	76	76	72
212931-LVIS	74	76	76	71
	3.0 mm OD	3.5 mm OD	4.0 mm OD	4.5 mm OD
213015-LVIS	78	79	79	77
213025-LVIS	78	79	78	74
213041-LVIS	77	78	78	73
	4.0 mm OD	4.5 mm OD	5.0 mm OD	5.5 mm OD
214035-LVIS	82	82	81	78
214049-LVIS	82	82	81	77

Table 1b: LVIS Jr. Device Product Information

LVIS Jr.					
Product Code	Undeployed Length† (mm)	Total Length/ Working Length** (mm)	Total Length/ Working Length** (mm)	Total Length/ Working Length** (mm)	Total Length/ Working Length** (mm)*
		2.0 mm OD	2.5 mm OD	3.0 mm OD	3.5 mm OD
172010-LVISJ	15	14 / 10	13 / 9		
172014-LVISJ	20	18 / 14	17 / 13		
172020-LVISJ	27	24 / 20	23 / 19		
172032-LVISJ	40	36 / 32	34 / 30		
172516-LVISJ	23		20 / 16	19 / 15	18 / 14
172524-LVISJ	31		27 / 23	25 / 21	23 / 19
172530-LVISJ	39		34 / 30	32 / 28	28 / 24
172537-LVISJ	46		40 / 36	37 / 33	33 / 29
Compatible with Headway 17 Microcatheter (inner diameter = 0.017" or 0.43 mm), Scepter C™ or Scepter XC™ Occlusion Balloons					
* Fully expanded diameter					
** Total Length (which includes flared ends) = working Length + 4 mm (2 mm each side)					
†Within Headway 17 Microcatheter (inner diameter = 0.017" or 0.43 mm)					

Product Code	LVIS Jr.				
	Free Area (%)				
	2.0 mm OD	2.5 mm OD	3.0 mm OD	3.5 mm OD	
172010-LVISJ	77	81			
172014-LVISJ	77	80			
172020-LVISJ	76	80			
172032-LVISJ	76	79			
172516-LVISJ			84	83	
172524-LVISJ			83	84	83
172530-LVISJ			83	85	83
172537-LVISJ			83	84	83

INDICATIONS FOR USE

The LVIS and LVIS Jr. devices are indicated for use with neurovascular embolization coils in patients ≥ 18 years of age for the treatment of wide-neck (neck width ≥ 4 mm or dome to neck ratio < 2) saccular intracranial aneurysms arising from a parent vessel with a diameter ≥ 2.0 mm and ≤ 4.5 mm.

CONTRAINDICATIONS

Use of the LVIS device is contraindicated under these circumstances:

- Patients in whom anticoagulant, anti-platelet therapy or thrombolytic drugs are contraindicated;
- Patients with known hypersensitivity to metal, such as nickel-titanium and metal jewelry;
- Patients with anatomy that does not permit passage or deployment of the LVIS device;
- Patients with an active bacterial infection;
- Patients with a pre-existing stent in place at the target aneurysm.

WARNINGS

Do not use device for acutely ruptured intracranial aneurysms within a minimum of 30 days from intracranial aneurysm rupture.

Should unusual resistance be felt at any time during access or removal, the introducer/microcatheter and LVIS device should be removed as a single unit. Applying excessive force during delivery or retrieval of the LVIS device can potentially result in loss or damage to the device and delivery components.

The LVIS device should only be used by physicians trained in endovascular interventional neuroradiology, radiology, neurosurgery or interventional neurology on the treatment of intracranial aneurysms.

Selection of the LVIS device size is important for proper product performance and patient safety and must be based on pre-treatment angiograms for correct and accurate vessel measurements from multiple views.

It is imperative to use the LVIS device with compatible microcatheters. If repeated friction is encountered during LVIS device delivery, verify microcatheter is not kinked or in extremely tortuous anatomy. Confirm that the microcatheter does not ovalize. Confirm that there is adequate sterile flush solution.

Do not reposition the LVIS device in the parent vessel without fully retrieving the device. The LVIS device MUST be retrieved into the microcatheter and re-deployed at the desired target location or removed completely from the patient.

Do not attempt to re-position the LVIS implant after detachment.

Do not shape the tip of the delivery wire.

Do not torque the delivery wire while advancing or retracting the LVIS device. A torque device should not be used.

PRECAUTIONS

The LVIS device is provided sterile for single use only. Do not reuse, reprocess or resterilize. Reuse, reprocessing or resterilization may compromise the structural integrity of the device and/or lead to device failure which, in turn, may result in patient injury, illness, or death. Reuse, reprocessing, or resterilization may also create a risk of contamination of the device and/or cause patient infection or cross-infection, including, but not limited to, the transmission of infectious disease(s) from one patient to another. Contamination of the device may lead to injury, illness or death of the patient.

Carefully inspect the sterile package and the LVIS device prior to use to verify that neither has been damaged during shipment. Do not use kinked or damaged components, or if the packaging is damaged.

See the product label for the device shelf life. Do not use the device beyond the labeled use by date.

Exercise caution when crossing the deployed/detached LVIS device with adjunctive devices such as guidewires, catheters, microcatheters or balloon catheters to avoid disrupting the device geometry and device placement.

The LVIS and LVIS Jr. devices with neurovascular embolization coils may create local field inhomogeneity and susceptibility artifacts during magnetic resonance angiography (MRA), which may degrade the diagnostic quality to assess effective intracranial aneurysm treatment.

The safety and effectiveness of the device has not been established in the treatment of large and giant wide-neck intracranial aneurysms.

The benefits may not outweigh the risks of treatment in patients with wide-neck intracranial aneurysms ≤ 5 mm in size, or reduced life expectancy, in the absence of additional risk factors for intracranial aneurysm rupture.

The safety and effectiveness of the device has not been well established in the posterior circulation.

Ensure that the specific embolization coil models and sizes used are indicated for the embolization of intracranial aneurysms.

Potential Adverse Events

The following potential risks and complications associated with general anesthesia, cerebral angiography, intracranial catheterization, intracranial stent placement or intra-saccular coil deployment have been identified below:

- Allergic reaction, including but not limited to: contrast dye, nitinol metal, and any other medications used during the procedure;
- Aphasia
- Blindness;
- Cardiac Arrhythmia;
- Coil prolapsed or migration into normal vessel adjacent to aneurysm
- Complications of arterial puncture including pain, local bleeding, local infection and injury to the artery, vein or adjacent nerves;
- Cranial neuropathy;
- Death;
- Device fracture, migration or misplacement;
- Dissection or perforation of the parent artery;
- Headache;
- Hemorrhage (i.e., intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH), or retroperitoneal (or in other locations));
- Hemiplegia;
- Hydrocephalus;
- Infection;
- Injury to normal vessel or tissue;
- Ischemia;
- Mass effect;
- Myocardial Infarction;

- Neurological deficits;
- Occlusion of non-target side branches;
- Pseudo aneurysm formation;
- Reactions to anti-platelet/anti-coagulant agents;
- Reactions due to radiation exposure;
- Reactions to anesthesia and related procedures;
- Reactions to contrast agents;
- Renal failure;
- Aneurysm rupture;
- Stenosis of stented segment;
- Seizure;
- Stent thrombosis;
- Stroke or TIA (Transient Ischemic Attack);
- Thromboembolic event (T/E);
- Vasospasm;
- Visual impairment.

Potential Risks Associated with X-ray Exposure: The use of the LVIS device requires fluoroscopy, which presents potential risks associated with X-ray exposure. The risks of angiographic and fluoroscopic X-ray radiation doses to the patient include risks such as alopecia, burns ranging in severity from skin reddening to ulcers, cataracts, and delayed neoplasia that increase in probability as procedure time and number of procedures increase. The probability of adverse event occurrence increases as the procedure time and the number of procedures increase. Operators should take all necessary precautions to limit X-ray radiation doses to patients and themselves by using sufficient shielding, reducing fluoroscopy times, and modifying X-ray technical factors whenever possible.

Summary of Adverse Events in Clinical Study

The CEC reviewed and adjudicated all adverse events in the LVIS study for nature, severity, seriousness, device and procedure relatedness. No unanticipated adverse device effects (UADE) occurred during this trial. A summary of adverse events is shown below. AEs are reported based on CEC adjudication. One hundred forty-five (145) events were reported during the peri-procedural period in 61 subjects. After 30 days (31 days to 12 months), 159 events occurred in 46 subjects. Serious adverse events separated into device or procedure related are also provided.

Overall Adverse Event Summary (independent of relatedness)*

Adverse Event	Peri Procedure		Post Procedure	
	# of Events	% of subjects with event (n/N)	# of Events	% of subjects with event (n/N)
Any Adverse Event	145	39.9% (61/153)	159	30.1% (46/153)
Cardiac	8	4.6% (7/153)	10	5.2% (8/153)
Cardiac arrhythmias	4	2.6% (4/153)	2	1.3% (2/153)
Death	0	0.0% (0/153)	1	0.7% (1/153)
Myocardial Infarction	0	0.0% (0/153)	1	0.7% (1/153)
Other	4	2.6% (4/153)	6	3.9% (6/153)
Gastrointestinal	2	1.3% (2/153)	13	5.9% (9/153)
Bleeding	0	0.0% (0/153)	2	0.7% (1/153)
Hemorrhage	1	0.7% (1/153)	0	0.0% (0/153)
Infection	0	0.0% (0/153)	1	0.7% (1/153)
Ischemia	0	0.0% (0/153)	1	0.7% (1/153)
Other	1	0.7% (1/153)	9	4.6% (7/153)

Adverse Event	Peri Procedure		Post Procedure	
	# of Events	% of subjects with event (n/N)	# of Events	% of subjects with event (n/N)
Infectious / Inflammatory	0	0.0% (0/153)	8	1.3% (2/153)
Infection	0	0.0% (0/153)	8	1.3% (2/153)
Musculoskeletal	9	5.2% (8/153)	17	9.8% (15/153)
Ischemia	0	0.0% (0/153)	1	0.7% (1/153)
Other	9	5.2% (8/153)	16	9.8% (15/153)
Neurological / Neurovascular	74	26.8% (41/153)	50	19.0% (29/153)
Aneurysm rupture	4	2.6% (4/153)	0	0.0% (0/153)
Aphasia	1	0.7% (1/153)	0	0.0% (0/153)
Device Failure	10	6.5% (10/153)	0	0.0% (0/153)
Dissection or perforation of the parent artery	2	1.3% (2/153)	0	0.0% (0/153)
Headache	9	5.2% (8/153)	8	4.6% (7/153)
Hydrocephalus	1	0.7% (1/153)	1	0.7% (1/153)
Intra-Parenchymal Hemorrhage	2	1.3% (2/153)	2	1.3% (2/153)
Neurological deficits	6	3.3% (5/153)	3	1.3% (2/153)
Other	5	3.3% (5/153)	12	7.2% (11/153)
Seizure	4	2.0% (3/153)	1	0.0% (0/153)
Stent Thrombosis	3	2.0% (3/153)	2	1.3% (2/153)
Stroke	6	3.3% (5/153)	6	3.3% (5/153)
Sub-Arachnoid Hemorrhage (SAH)	2	1.3% (2/153)	1	0.7% (1/153)
Sub-Dural Hematoma (SDH)	1	0.7% (1/153)	2	1.3% (2/153)
TIA (Transient Ischemic Attack)	3	2.0% (3/153)	3	2.0% (3/153)
Target aneurysm retreatment	0	0.0% (0/153)	6	3.9% (6/153)
Thromboembolic event	1	0.7% (1/153)	0	0.0% (0/153)
Vasospasm	10	5.9% (9/153)	0	0.0% (0/153)
Visual impairment	4	1.3% (2/153)	3	2.0% (3/153)
Other	22	10.5% (16/153)	35	11.8% (18/153)
Allergic reaction	1	0.7% (1/153)	0	0.0% (0/153)
Bleeding	2	1.3% (2/153)	0	0.0% (0/153)
Death	0	0.0% (0/153)	1	0.7% (1/153)
Headache	0	0.0% (0/153)	1	0.7% (1/153)
Infection	0	0.0% (0/153)	1	0.7% (1/153)
Other	17	8.5% (13/153)	31	9.2% (14/153)
Reactions due to radiation exposure	1	0.7% (1/153)	0	0.0% (0/153)
Reactions to anesthesia and related procedures	1	0.7% (1/153)	0	0.0% (0/153)
Visual impairment	0	0.0% (0/153)	1	0.7% (1/153)
Renal / Genitourinary	5	3.3% (5/153)	8	3.9% (6/153)
Infection	3	2.0% (3/153)	2	0.7% (1/153)
Other	2	1.3% (2/153)	5	3.3% (5/153)
Renal failure	0	0.0% (0/153)	1	0.7% (1/153)
Respiratory / Pulmonary	8	5.2% (8/153)	13	4.6% (7/153)
Death	0	0.0% (0/153)	1	0.7% (1/153)
Emboli	0	0.0% (0/153)	1	0.7% (1/153)
Infection	3	2.0% (3/153)	1	0.7% (1/153)
Other	5	3.3% (5/153)	10	3.9% (6/153)
Vascular	17	11.1% (17/153)	5	3.3% (5/153)
Bleeding	4	2.6% (4/153)	1	0.7% (1/153)
Complications of arterial puncture	9	5.9% (9/153)	0	0.0% (0/153)
Ecchymosis	0	0.0% (0/153)	2	1.3% (2/153)
Hemorrhage	2	1.3% (2/153)	0	0.0% (0/153)
Other	2	1.3% (2/153)	1	0.7% (1/153)
Vascular complication	0	0.0% (0/153)	1	0.7% (1/153)

* Percentages are based on the # of subjects effected and some subjects may have more than one event.

Serious Device Related Adverse Events*

Adverse Event	Peri Procedure		Post Procedure	
	# of Events	% of subjects with event (n/N)		# of Events
Any Serious Device Related Adverse Events	22	11.1% (17/153)	5	3.3% (5/153)
Neurological / Neurovascular	22	11.1% (17/153)	5	3.3% (5/153)
Device Failure	6	3.9% (6/153)	0	0.0% (0/153)
Dissection or perforation of the parent artery	1	0.7% (1/153)	0	0.0% (0/153)
Other	3	2.0% (3/153)	0	0.0% (0/153)
Stent Thrombosis	3	2.0% (3/153)	2	1.3% (2/153)
Stroke	4	2.6% (4/153)	2	1.3% (2/153)
TIA (Transient Ischemic Attack)	1	0.7% (1/153)	1	0.7% (1/153)
Vasospasm	1	0.7% (1/153)	0	0.0% (0/153)
Visual impairment	3	1.3% (2/153)	0	0.0% (0/153)

* Percentages are based on the # of subjects effected and some subjects may have more than one event.

Serious Procedure Related Adverse Events*

Adverse Event	Peri Procedure		Post Procedure	
	# of Events	% of subjects with event (n/N)	# of Events	% of subjects with event (n/N)
Any Serious Procedure Related Adverse Events	61	28.8% (44/153)	8	3.9% (6/153)
Cardiac	1	0.7% (1/153)	0	0.0% (0/153)
Cardiac arrhythmias	1	0.7% (1/153)	0	0.0% (0/153)
Gastrointestinal	1	0.7% (1/153)	1	0.7% (1/153)
Bleeding	0	0.0% (0/153)	1	0.7% (1/153)
Hemorrhage	1	0.7% (1/153)	0	0.0% (0/153)
Neurological / Neurovascular	43	20.9% (32/153)	6	2.6% (4/153)
Aneurysm rupture	4	2.6% (4/153)	0	0.0% (0/153)
Aphasia	1	0.7% (1/153)	0	0.0% (0/153)
Device Failure	9	5.9% (9/153)	0	0.0% (0/153)
Dissection or perforation of the parent artery	1	0.7% (1/153)	0	0.0% (0/153)
Hydrocephalus	1	0.7% (1/153)	0	0.0% (0/153)
Intra-Parenchymal Hemorrhage	2	1.3% (2/153)	0	0.0% (0/153)
Neurological deficits	2	1.3% (2/153)	0	0.0% (0/153)
Other	1	0.7% (1/153)	0	0.0% (0/153)
Seizure	1	0.7% (1/153)	0	0.0% (0/153)
Stent Thrombosis	3	2.0% (3/153)	0	0.0% (0/153)
Stroke	5	3.3% (5/153)	1	0.0% (0/153)
Sub-Arachnoid Hemorrhage (SAH)	2	1.3% (2/153)	0	0.0% (0/153)
TIA (Transient Ischemic Attack)	1	0.7% (1/153)	1	0.7% (1/153)
Target aneurysm retreatment	0	0.0% (0/153)	3	2.0% (3/153)
Thromboembolic event	1	0.7% (1/153)	0	0.0% (0/153)
Vasospasm	7	4.6% (7/153)	0	0.0% (0/153)
Visual impairment	2	1.3% (2/153)	1	0.7% (1/153)
Other	4	2.6% (4/153)	1	0.7% (1/153)
Other	4	2.6% (4/153)	1	0.7% (1/153)
Renal / Genitourinary	2	1.3% (2/153)	0	0.0% (0/153)
Infection	2	1.3% (2/153)	0	0.0% (0/153)
Respiratory / Pulmonary	3	2.0% (3/153)	0	0.0% (0/153)
Infection	1	0.7% (1/153)	0	0.0% (0/153)
Other	2	1.3% (2/153)	0	0.0% (0/153)
Vascular	7	4.6% (7/153)	0	0.0% (0/153)
Bleeding	2	1.3% (2/153)	0	0.0% (0/153)
Complications of arterial puncture	4	2.6% (4/153)	0	0.0% (0/153)
Hemorrhage	1	0.7% (1/153)	0	0.0% (0/153)

* Percentages are based on the # of subjects effected and some subjects may have more than one event.

Summary of Clinical Study

Design:

The study was a multi-center, prospective, single-arm study with follow-up at hospital discharge, 30 days, 6 months and 12 months post procedure. There were twenty-two (22) investigational sites all within the United States.

Inclusion/Exclusion Criteria:

Inclusion Criteria

Subjects were included if they met the following criteria:

- Subject whose age is ≥ 18 and ≤ 75 years;
- Subject with an unruptured or ruptured (> 30 days since occurrence), wide-necked (neck ≥ 4 mm or dome to neck ratio < 2) intracranial, saccular aneurysms (≥ 4 mm and < 20 mm maximum diameter in any plane) arising from a parent vessel with a diameter ≥ 2.0 mm and ≤ 4.5 mm who are candidates for endovascular coil embolization;
- Subject or his/her Legally Authorized Representative understands the nature of the procedure, consents to participation in the study and provides a signed informed consent form;
- Subject (woman of child-bearing potential) with a current negative pregnancy test who has agreed to an appropriate method of contraception throughout the trial;
- Subject lives at a permanent address within commuting range of the investigational site and will be residing at that address during their 12 months of study participation;
- Subject is willing to return to the investigational site for the 30-day, 6-month and 12-month follow-up evaluations.

Exclusion Criteria

Subjects were excluded if any of the following conditions existed:


- Subject who presents with ruptured aneurysm, unless rupture occurred 30 days or more prior to screening;
- Subject who presents with an intracranial mass (other than a meningioma) or currently undergoing radiation therapy for carcinoma or sarcoma of the head or neck region;
- Subject with significant extracranial or intracranial stenosis of the parent artery ($> 50\%$) proximal to the target aneurysm;
- Subject with an irreversible bleeding disorder, a platelet count of less than 100,000/ml ($< 100 \times 10^3$ cells/mm³) or known platelet dysfunction or a contraindication to or inability to tolerate anticoagulants and/or antiplatelet agents;
- Subject with serum creatinine level > 3.0 mg/dL at time of enrollment (this will restrict the use of contrast) and not on dialysis;
- Subject with known allergies to nickel-titanium metal; jewelries
- Subject with known allergies or contraindications to required anti-platelet and/or heparin medications required for treatment;
- Subject with a life-threatening allergy to radiographic contrast (unless treatment for allergy is tolerated or can be managed medically);
- Subject with a contraindication to CT (Computed Tomography) and MRI (Magnetic Resonant Imaging);
- Subject who has a known cardiac disorder, likely to be associated with cardioembolic symptoms such as AFIB (atrial fibrillation);
- Subject with any condition which in the opinion of the treating physician would place the Subject at a high risk of embolic stroke;
- Subject who is currently participating in another clinical research study with a conflicting protocol;
- Subject who has had a previous intracranial stenting procedure associated with the target aneurysm;
- Subject who is unable to complete the required follow-up;

- Subject who is pregnant or breastfeeding;
- Subject who has participated in a drug study within the last 30 days.

Angiographic Exclusion Criteria

- Subject has a cerebral diagnostic angiogram that demonstrates an aneurysm that is not appropriate for endovascular treatment;
- Subject has a fusiform or dissecting aneurysm;
- Subject is harboring more than one aneurysm with each aneurysm requiring treatment within 30 days;
- Subject has an arteriovenous malformation (AVM) in the territory of the target aneurysm.

Subject Accountability Flowchart:



[1] Subject 01-04 died on day 2

[2] Subject 22-05 had a missed 30 day visit

[3] Subject 01-05 died on day 63

[4] Subjects 06-25, 09-02, 11-03, 12-04, 12-06, and 19-23 missed the 6 month visit

[5] Subject 03-03 died on day 393; however, this subject completed the 12 month follow-up visit and is included.

[6] Subjects 06-25 and 05-05 had a 12 month visit. 06-25 did not have an angiogram, 05-05 had an angiogram that was not evaluable.

Demographics:

The demographic characteristics of the Intent-to-Treat (ITT) population are shown below. The mean age was 58.3±10.49 years and the majority of subjects (110/153, 71.9%) were women. The demographic characteristics are consistent with typical cohort of subjects undergoing treatment of intracranial, saccular aneurysms.

Demographic Characteristics

Characteristic	Summary Statistic
Age (years)	
Mean ± std (n)	58.3 ± 10.49 (153)
Median (min, max)	59.0 (18, 75)
Gender, % (n/N)	
Male	28.1% (43/153)
Female	71.9% (110/153)
Race, % (n/N)	
American Indian or Alaska Native	0.7 % (1/153)
Asian	1.3 % (2/153)
Black or African American	15.7% (24/153)
Native Hawaiian or other Pacific Islander	0.0 % (0/153)
White	80.4% (123/153)
Other	2.0 % (3/153)
Missing	0.7 % (1/153)

Aneurysm Characteristics:

Location and Sublocation	% of subjects (n/N)
Internal Carotid Artery	28.1% (43/153)
Carotid Cavernous	2.0% (3/153)
Carotid Ophthalmic	5.9% (9/153)
Superior Hypophyseal	6.5% (10/153)
Posterior Communication Artery	5.9% (9/153)
Anterior Choroidal Artery	1.3% (2/153)
Internal Carotid Artery (Supraclinoid)	4.6% (7/153)
Carotid Bifurcation	2.0% (3/153)
Anterior Cerebral Artery	37.3% (57/153)
Anterior Communicating Artery	33.3% (51/153)
Pericallosal	3.9% (6/153)
Middle Cerebral Artery	11.1% (17/153)
Posterior Cerebral Artery	3.9% (6/153)
Basilar Artery	17.6% (27/153)
Basilar Tip	17.0% (26/153)
Anterior Inferior Cerebellar Artery	0.0% (0/153)
Basilar Trunk	0.7% (1/153)
Superior Cerebellar Artery	0.7% (1/153)
Vertebral Artery	1.3% (2/153)
Posterior Inferior Cerebellar Artery (PICA)	0.7% (1/153)
VB Junction	0.7% (1/153)

Characteristic	Mean ± std (n)	Median (min, max)
Dome Height	6.0 ± 2.15(153)	5.8 (2.0,14.0)
Dome Width (perpendicular to height)	5.5 ± 2.33(153)	5.0 (1.4,17.0)
Neck Width	4.2 ± 1.41(153)	4.0 (1.8,10.0)
Dome to Neck Ratio	1.3 ± 0.38(153)	1.3 (0.5,3.3)
Distal Parent Artery Diameter (landing zone)	2.5 ± 0.64(153)	2.2 (1.6,4.8)
Proximal Parent Artery Diameter (landing zone)	2.8 ± 0.70(153)	2.5 (2.0,4.5)
Mean Parent Artery Diameter	2.6 ± 0.64(153)	2.4 (2.0,4.6)

Primary Safety Results:

The pre-specified primary safety endpoint was defined as the composite rate of major stroke or death within 30 days or major ipsilateral stroke or neurologic death with 12 months. Beyond the original primary safety and effectiveness endpoint analysis, additional analyses were conducted based upon a modified primary safety endpoint. The modified primary safety endpoint is defined as the composite rate of neurological death and any disabling stroke within 12 months post-treatment with the LVIS device. A disabling stroke is defined by a modified Rankin Scale (mRS) score ≥ 3 at a minimum of 90 days post-stroke event. Eight subjects (5.2%, 8/153) had at least one primary safety event per the pre-specified primary safety endpoint and nine subjects (5.9%, 9/153) had at least one primary safety event per the modified primary safety endpoint in the ITT population. Thus, the success criterion of the pre-established safety Performance Goal (PG) for the pre-specified and modified primary safety endpoints was achieved.

Primary Safety Endpoint using the modified endpoint analysis (Disabling Stroke or neurological death within 12 months)

Event Type	% of Subjects with Observations (n/N)	Posterior Mean, 95% CI [1]	Posterior Probability [2]
Primary Safety Composite Rate* (Disabling stroke with mRS score ≥ 3 or neurological death within 12 months)	5.9 % (9/153)	6.2% 3.0% - 10.5%	1
Primary Safety Failure Reasons [3]			
Disabling stroke with mRS score ≥ 3 through 12 months*	3.9 % (6/153)	4.2% 1.7% - 7.9%	NA
Neurological death through 12 months	2.0 % (3/153)	2.3% 0.6% - 5.1%	NA

[1] Posterior mean and 95% Credible Interval (CI). The confidence intervals are calculated without multiplicity adjustment. As such, the confidence intervals are provided to show the variability only and should not be used to draw any statistical conclusions.

[2] Posterior probability that the primary safety endpoint event rate is less than the pre-specified PG.

[3] Subjects may have more than one failed safety component. Three (3) subjects with stroke expired from neurological deaths.

[*] mRS score ≥ 3 at any time point between 90 days and last available follow-up.

Primary Effectiveness Results:

The pre-specified primary effectiveness endpoint was defined as successful intracranial aneurysm treatment with the LVIS device as evidenced by complete (100%) aneurysm angiographic occlusion at 12 months without retreatment and no significant ($\geq 50\%$) stenosis of the treated artery at 12 months. The modified primary effectiveness endpoint is defined as the rate of 90-100% aneurysm angiographic occlusion at 12 months (equivalent to Raymond-Roy I and stable Raymond-Roy II occlusion assessed via two imaging scans taken at a minimum of 6 months apart) without retreatment and no significant ($\geq 50\%$) stenosis of the treated artery at 12 months. The modified primary effectiveness analysis most closely aligns with the recommendations provided by the Neurological Devices Panel of the Medical Devices Advisory Committee following the March 1, 2018 meeting convened by FDA to provide scientific and clinical considerations relating to the determination and evaluation of the safety and effectiveness of novel endovascular aneurysm treatment devices for marketing approval in the United States (US).

The effectiveness results show that 70.6% (108/153) of patients in the “Pivotal Study of the MicroVention, Inc. Neurovascular Self-Expanding Retrievable Stent System LVIS in the Treatment of Wide-Necked Intracranial Artery Aneurysms” had complete (100%) intracranial aneurysm occlusion without clinically significant in-stent stenosis or retreatment of the target aneurysm, an additional 10.4% (16/153) patients had stable or improved Raymond-Roy II intracranial aneurysm occlusions without clinically significant in-stent stenosis or target aneurysm treatment, for a total composite effectiveness rate of 81.0% (124/153).

For the additional ITT evaluable analysis (patients who were angiographically evaluated at the 12-month follow-up), 77.7% (108/139) of the subjects met the prespecified and 89.2% (124/139) met the modified primary effectiveness success criteria exceeding the prospectively established effectiveness PG. None of the 139 evaluable subjects had clinically significant In-Stent Stenosis at 12-month follow-up. Thus, the success criterion of the pre-established effectiveness Performance Goal (PG) for the pre-specified and modified primary effectiveness endpoints was achieved.

Primary Effectiveness Endpoint using the modified endpoint analysis (90-100% aneurysm occlusion without clinically significant In Stent Stenosis or Target Aneurysm Retreatment)

Endpoint [1]	% of Subjects with Observations (n/N)	Posterior Mean, 95% CI [2]	Posterior Probability [3]
Imputed Analysis per the Prespecified Primary Effectiveness Endpoint			
Primary Effectiveness Composite Success (100% aneurysm occlusion without clinically significant In Stent Stenosis or Target Aneurysm Retreatment)	70.6% (108/153)	70.5% 63.0% – 77.4%	1
Imputed Analysis per the Modified Primary Effectiveness Endpoint			
Modified Primary Effectiveness Composite Success (90% - 99% aneurysm occlusion without clinically significant In Stent Stenosis or Target Aneurysm Retreatment) Σ	10.4% (16/153)		
Modified Primary Effectiveness Composite Success (90% - 100% aneurysm occlusion without clinically significant In Stent Stenosis or Target Aneurysm Retreatment)	81.0% (124/153) [124 = 108 + 16]	80.8% 74.3% - 86.6%	1
Primary Effectiveness Endpoint Subcomponents			
90%-100% aneurysm occlusion*	83.7% (128/153)	83.4% 77.2% - 88.9%	NA
Without Clinically Significant In Stent Stenosis ($\geq 50\%$) of Parent Artery	90.8% (139/153)	90.6% 85.5% - 94.7%	NA
No Target Aneurysm Retreatment	96.1% (147/153)	95.8% 92.1% - 98.4%	NA
Evaluable Only Analysis per the Prespecified Primary Effectiveness Endpoint			
Primary Effectiveness Composite Success (100% aneurysm occlusion without clinically significant In Stent Stenosis or Target Aneurysm Retreatment)	77.7% (108/139)	77.5% 70.3% - 84%	1

Evaluable Only Analysis per the Modified Primary Effectiveness Endpoint			
Modified Primary Effectiveness Composite Success (90% - 99% aneurysm occlusion without clinically significant In Stent Stenosis or Target Aneurysm Retreatment) Σ	11.5% (16/139)		
Modified Primary Effectiveness Composite Success (90% - 100% aneurysm occlusion without clinically significant In Stent Stenosis or Target Aneurysm Retreatment)	89.2% (124/139) [124 = 108 + 16]	82.5% 75.3% - 88.6%	1
Modified Primary Effectiveness Composite Success (90% - 100% aneurysm occlusion without clinically significant In Stent Stenosis or Target Aneurysm Retreatment) using only DSA at 12 months Υ	88.6% (117/132) [124-7 / 139-7]	88.3% 75.3% - 88.6%	1
Primary Effectiveness Endpoint Subcomponents			
90%-100% aneurysm occlusion*	91.4% (127/139)	91.2% 84.4% - 97.4%	NA
Without Clinically Significant In Stent Stenosis (\geq 50%) of Parent Artery	100.0% (139/139)	99.6% 98.2% - 100%	NA
No Target Aneurysm Retreatment	95.7% (133/139)	95.4% 91.3% - 98.2%	NA

Σ Only subjects with stable or positively progressing Raymond-Roy II occlusion between baseline and 12 months are included.

Υ Seven subjects who were assessed using MRA in lieu of DSA are excluded.

[1] Includes primary effectiveness data collected on all ITT subjects at or through 12-month follow-up visit.

[2] Posterior mean and two-sided 95% CI. The confidence intervals are calculated without multiplicity adjustment. As such, the confidence intervals are provided to show the variability only and should not be used to draw any statistical conclusions.

[3] Posterior probability that the primary effectiveness endpoint success rate exceeds the pre-specified PG at 12 months.

*Subjects having negative progression from post-procedure to 12 months are considered failures. Missing data imputed as failures.

Analysis of Subjects with Stroke Events and Worsening mRS Scores:

Subject mRS scores for all strokes in the LVIS study*

#	Subject ID	mRS pre-procedure baseline	mRS at Discharge	mRS at 30 days	mRS at 180 days	mRS at 12 months
Strokes resulting in neurological death						
1	01-04	0	mRS = 6, neurological death	n/a	n/a	n/a
2	01-05	0	0	0	mRS = 6, neurological death	n/a
3	03-03 €	0	0	Not done	0	mRS = 0 at 12 months. Subject expired from a neurological cause 393 days post-procedure
Disabling strokes (mRS ≥ 3 at a minimum of 90 days)						
4	03-02 ‡	0	4	1	3	1
5	09-09 €	0	3	2	2	3
6	12-04	3	3	4	Not done	4
7	14-18	1	1	0	5	5
Disabling strokes caused by pre-existing conditions						
8	03-18 ‡	1	1	0	3	1
9	04-09	3	3	3	3	3
Non-Disabling strokes						
10	03-03 €	0	0	Not done	0	0
11	03-19	1	1	1	1	0
12	06-07	0	0	1	1	0
13	09-05	1	1	1	1	1
14	09-09 €	0	3	2	2	3
15	09-13	0	0	0	0	0
16	16-01	0	0	1	0	0

* 16 strokes occurred in 14 subjects

€ Subjects 03-03 & 09-09 each sustained both a minor stroke peri-operatively and a major stroke post-operatively

‡ Subjects 03-02 & 03-18 sustained strokes that did not result in permanent neurological disability.

At 12 months, 25 subjects (16%, 25/153) had mRS scores which worsened as compared to their baseline scores. Reason for change is described in the table. Fourteen (14) out of the 25 patients (9.2%, 14/153) experienced deterioration in the mRS score at 12 months post-procedure that affected their clinical disability level (mRS ≥ 3). The recorded events that result in clinical deterioration (mRS ≥ 3) included events caused by deficits which occurred following study participation as well as events of non-neurological causes and deficits caused by pre-existing patient conditions (see table).

LVIS Subjects (N=25) with worsening mRS scores at 12 months as compared to baseline

Worsening mRS score by category	Baseline mRS	Discharge mRS	mRS at 30 days	mRS at 6 months	mRS at 12 months	Reason for Change
Neurological Death						
1€	0	6				
2€	0	0	0			
3€	0	0		0	0	
Non-neurological Death						
4€	1	1	1			Cardiac arrest
5€	0	0	0			Drug overdose
6€	2	2	2			Suicide
Neurological decline from new neurological deficits						
7	0	3	2	2	3	Ataxia, Major Stroke
8	1	1	0	5	5	Major stroke
9	0	0	0		4	Subdural Hematoma
10	0	0	0	2	3	New diagnosis of multiple sclerosis
11	2	2	1	0	3	Depression
12	3	4	4	3	4	General Debilitation from visual impairment, anxiety, depression
Neurological decline from pre-existing neurological deficits						
13	1	1	1	3	3	Preexisting neuropathy
14	1	1	1	1	2	General debilitation from right upper intrinsic weakness, right leg weakness, mild motor aphasia
15	3	3	4		4	Preexisting bilateral leg paresthesia & weakness
Other (no new neurological deficit)						
16	0	0	0	1	1	Lightheaded episode
17	0	4	1	3	1	Left foot weakness
18	0	1	0	0	1	Persisting headaches
19	0	0	0	1	1	Left-sided weakness
20	0	0	0	0	1	Headaches & Fatigue
21	0	0	0	1	1	Arthritis
22	0	0	0	1	1	Dizziness
23	0	0	1	1	1	Exacerbation of preexisting low back pain
24	0	0	1	1	1	Headaches & dizziness
25	0	0	0	0	2	Fatigue, CPAP issues

Six subjects footnoted above died throughout the course of the LVIS study:

€ Subject (1) died 2 days post procedure, subject (2) died 63 days post procedure, subject (3) died 393 days post procedure, subject (4) died 310 days post procedure, subject (5) died 92 days post procedure, subject (6) died 202 days post procedure.

Conclusion:

The clinical study results support the reasonable assurance of safety and effectiveness of this device when used in accordance with the indications for use. The overall risk to benefit ratio is favorable for the intended population.

SYMBOLS



Consult instructions for use



Caution



Lot Number



Catalog Number



Contents



Sterilized Using Irradiation



Do Not Reuse



Use-by Date



Date of Manufacture



Manufacturer



MR Conditional



Non-pyrogenic



Do Not Use if Package is Damaged

MR Information



Non-clinical testing has demonstrated that the LVIS device is **MR conditional**. A patient with this device can be safely scanned in a MR system meeting the following conditions:

- Static magnetic field of 1.5 Tesla and 3 Tesla only
- Maximum spatial gradient magnetic field of 2,500 Gauss/cm
- Maximum MR system reported, whole body averaged specific absorption rate (SAR) of 2 W/kg (Normal Operating Mode)

Under the scan conditions defined above, the LVIS device is expected to produce a maximum temperature rise of 2.8°C at 1.5T or 3.6°C at 3T after 15 minutes of continuous scanning.

In non-clinical testing, the image artifact caused by the device extends approximately 4 mm from the LVIS device when imaged with a gradient echo pulse sequence and a 3 Tesla MRI system.

CLINICIAN USE INFORMATION

Materials

The following parts are required to use the LVIS device:

- LVIS device should be introduced only by Headway 21 Microcatheter (0.021 inch inner diameter)

The following parts are required to use the LVIS Jr. device:

- LVIS Jr. device should be introduced only Headway 17 Microcatheter (0.017 inch inner diameter) or a Scepter C / Scepter XC Occlusion Balloon (0.0165 inch inner diameter)

Other accessories for performing a procedure and NOT supplied; to be selected based on the physician's experience and preferences:

- Appropriate-sized Guiding catheter for use with selected microcatheter
- Headway 21 microcatheter or Headway 17 microcatheter
- Scepter C / Scepter XC Occlusion Balloon
- Microcatheter-compatible guidewires
- Saline solution/heparin-saline solution continuous flush set
- Contrast solution
- Rotating Hemostatic Valve (RHV)
- Pressurized sterile Infusion solutions – IV stand
- Femoral arterial sheath, compatible with delivery guide catheter
- Femoral artery access device, sterile needle, guidewire

The LVIS device does not contain latex or PVC materials.

PACKAGING AND STORAGE

The LVIS device is placed inside a protective, plastic dispenser coil and packaged in a pouch and unit carton. The LVIS device and dispenser coil will remain sterile unless the package is opened, damaged, or the expiration date has passed. Store at a controlled room temperature in a dry place.

SHELF LIFE

See the product label for the device shelf life. Do not use the device beyond the labeled use by date.

PREPARATION FOR USE

Device and Delivery System Selection

Appropriate selection of the LVIS device is important for patient safety. In order to choose the optimal LVIS device model size for any given lesion, examine pre-treatment angiograms for correct and accurate vessel measurements.

HOW SUPPLIED

Sterile: This device is sterilized with E-Beam irradiation. Non-pyrogenic

Contents: One (1) LVIS device or one (1) LVIS Jr. device

Storage: Store product in a dry, cool place.

Note: A proper push/pull technique, encompassing sufficient delivery wire push force, in addition to an opposing microcatheter withdrawal force, will facilitate properly deploying the LVIS device to achieve full expansion and good vessel apposition.

Note: Slowly advancing the LVIS device while adjusting the microcatheter position will ensure accurate deployment. Maintain simultaneous control of the LVIS device and microcatheter in order to position and expand the device at the proper location.

Caution: Using a rapid microcatheter withdrawal technique to deploy the LVIS device is not recommended and may result in device elongation.

19. If LVIS device positioning is not satisfactory, the LVIS device may be recaptured and repositioned if it is not fully deployed. The LVIS device may be recaptured until the point where the proximal end of the LVIS device markers are aligned 3 mm proximally with the microcatheter distal marker band (approximately 75% deployed). [Figure 7]

Caution: If resistance is felt while recapturing the LVIS device, do not continue to recapture the device. Withdraw the microcatheter slightly to unsheath the LVIS device (without exceeding the recapture limit), and then attempt to recapture the LVIS device.

Caution: The LVIS device must not be re-deployed more than three times.

Note: The LVIS device delivery wire should not be utilized as a guidewire after stent deployment. Do not torque the LVIS device. A torque device should not be used.

20. If LVIS device positioning is satisfactory, carefully retract the microcatheter and advance the delivery wire together, to allow the LVIS device to deploy across the neck of the aneurysm. Ensure the device proximal radiopaque end markers are sufficiently proximal to the aneurysm neck to ensure an adequate landing zone. The LVIS device will expand and total length may foreshorten up to 60% from its undeployed length (refer to Table 1a/b) as it exits the microcatheter. Ensure microcatheter is retracted and clear from the proximal flared ends.

Note: Visualize and refer to the implant radiopaque end markers to maintain adequate implant length on each side of the aneurysm neck or target location to ensure appropriate neck coverage. [Figure 8]

Warning: Do not detach the LVIS device if it is not properly positioned in the parent vessel. Observe the delivery wire distal tip to assure it remains within the desired location of the parent vessel.


21. Prior to removing the delivery wire and if necessary, carefully position the microcatheter distal to the LVIS device to maintain access through the LVIS device. Remove and discard the delivery wire.

Warning: The LVIS device delivery wire should not be utilized as a guidewire. Do not torque the LVIS device. A torque device should not be used.

22. Deploy coils per standard interventional techniques.

Caution: Use caution when positioning and withdrawing the microcatheter used for coil placement to ensure that the stent is not displaced.

23. After placing the last coil, verify that the LVIS device has remained patent and properly positioned. After completing the procedure, withdraw and discard all applicable accessory devices.




Check for the following:

- Implant distal marker uniformity
- Implant distal end shows even displacement with no entanglement
- Implant tracks smoothly through introducer


Warning: DO NOT FULLY DEPLOY LVIS device.

[Figure 3b. Step 10b]



13. Verify that fluid exits the proximal end of the introducer

[Figure 4. Step 13]



[Figure 5. Step 14]



18. Position distal markers sufficiently distal to the aneurysm neck

[Figure 6. Step 18]



19. The LVIS device can be recaptured and repositioned if not yet fully deployed

[Figure 7. Step 19]



20. Ensure sufficient proximal landing zone from aneurysm neck.

[Figure 8. Step 20]

WARRANTY DISCLAIMER

MicroVention warrants that reasonable care has been used in the design and manufacture of this device. This warranty is in lieu of and excludes all other warranties not expressly set forth herein, whether expressed or implied by operation of law or otherwise, including, but not limited to, any implied warranties of merchantability or fitness for particular purpose. Handling, storage of the device as well as factors relating to the patient, diagnosis, treatment, surgical procedure, and other matters beyond MicroVention's control directly affect the device and the results obtained from its use. MicroVention's obligation under this warranty is limited to the replacement of this device through its expiration date. MicroVention shall not be liable for any incidental or consequential loss, damage or expense directly or indirectly arising from the use of this device. MicroVention neither assumes, nor authorizes any other person to assume for it, any other or additional liability or responsibility in connection with this device. MicroVention assumes no liability with respect to devices reused, reprocessed or resterilized or used after the expiration date stated on product label and makes no warranties, expressed or implied, including, but not limited to, merchantability or fitness for intended use, with respect to such device.

Prices, specifications, and model availability are subject to change without notice.

© Copyright 2021 MicroVention, Inc. All rights reserved.

MicroVention™, LVIS™, Headway™, Scepter C™ and Scepter XC™ are trademarks of MicroVention, Inc., registered in the United States and other jurisdictions.



Manufacturer:

MicroVention, Inc.

35 Enterprise,

Aliso Viejo, CA 92656 USA

Tel: 714.247.8000

www.microvention.com